How much weight can you lose with Retatrutide?

Retatrutide is a triple hormone (GIP, GLP-1 and glucagon) receptor agonist in development for the treatment of obesity. It has been dubbed the “triple G” drug because of the 3 hormones it mimics. Phase 2 trial results that were published in The New England Journal of Medicine included adults who were obese or overweight. It showed that those taking retatrutide lost up to 17.5%, or 41 lb of their baseline body weight at 24 weeks. This was compared to 1.6% in those taking the placebo. After 48 weeks, patients lost an average of 24.2% or 58 lb, compared to just 2.1% in the placebo group. Researchers believe the weight loss does not plateau at 48 weeks, so a longer study could show even greater weight loss. Currently, retatrutide is in Phase 3 trials that could be released by the end of this year. Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients. CNBC. Accessed June 10, 2025.